Cancer pain should never be accepted as an unavoidable price of the disease.
Cancer pain affects 55% of patients receiving anticancer treatment and nearly 66% of those with advanced or terminal cancer. Yet many continue to suffer silently!!
Pain is often neglected because:
treatment focuses on controlling the tumour, while pain assessment receives less attention
patients may under-report symptoms, believing that pain signals progression,
that strong medicines should be “saved for the end,” or
that morphine inevitably causes addiction, sleepiness or hastens death.
Restricted opioid access, inadequate training and delayed referral to pain specialists further widen the treatment gap.
Every person deserves pain relief, quality of life and the dignity of facing advanced illness without needless suffering.
WHO defines the goal as reducing pain enough to permit an acceptable quality of life.
The WHO analgesic ladder transformed cancer pain care by matching treatment to pain severity: non-opioid medicines for mild pain, opioids for moderate or severe pain, with supportive medicines added when required.
Modern adaptations of the ladder include interventional pain procedures as a fourth step. These may involve nerve or plexus blocks, neurolysis, radiofrequency procedures, epidural or intrathecal drug delivery and, in selected cases, cordotomy.
Importantly, they should not always be delayed until every medicine has failed.
Today, the ladder is used flexibly: severe pain may justify starting higher, achieving rapid control, and then stepping down as symptoms improve.
Cancer care must protect comfort as well as survival. Seek specialist pain care early—relief, function and dignity should remain central at every stage.
